Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2011
This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals\' (formerly SB Biologicals\') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix penta™) and Hib (Hiberix™) vaccine administered at 3, 5 and 11 (or 12) months of age.
Epistemonikos ID: 6cfdc0f6f32497b5faebb0e8a73a0b4cdfaa2de1
First added on: Nov 24, 2021